• news.cision.com/
  • CLS/
  • CLS Signs Exclusive Distribution Agreement with MRI Interventions for USA and Canada

CLS Signs Exclusive Distribution Agreement with MRI Interventions for USA and Canada

Report this content

Clincial Laserthermia Systems AB (publ) (CLS) and MRI Interventions (MRIC), today announced that the companies have signed an agreement granting MRI Interventions the exclusive right to distribute and sell CLS’s portfolio of products, including its TRANBERG® product line for high precision ablation, in the USA and Canada. This new two-year agreement includes all interventional MR-guided procedures beyond the previously announced license agreement for spine and neurosurgery.

“In line with CLS’s ambition to continue building its precision ablation business within interventional MR, MRI Interventions Inc has been selected as CLS’s distribution partner for USA and Canada. MRI Interventions is well-established, with a long and deep experience in marketing and sales of their ClearPoint® product portfolio to hospitals and clinicians, active within this space. We are excited about the immediate potential in this partnership and look forward to teaming up with this great company,” stated Dan Mogren, Chief Commercial Officer of CLS. 

“The distribution agreement expands the partnership beyond the license and collaboration agreement our two companies recently entered into, and it gives CLS immediate access to a team of +20 commercial managers and clinical specialists and their extensive business network,” says Lars-Erik Eriksson, CEO of CLS.

“This is an exciting collaboration for MRI,” commented Joe Burnett, President and CEO of MRI Interventions. “In addition to our previously announced co-development partnership and license for neurosurgery and spine, this agreement allows us to support the CLS platform beyond neurosurgery. MRI will leverage its existing commercial infrastructure to achieve scale and represent a great technology with our very capable team. This collaboration is a terrific tool to continue both parties path to profitability.” 

In collaboration with its customers and partners, CLS intends to continue expanding its product portfolio and offer unique products that will advance image guided ablation into a more precise, predictable, safe and effective therapy. This will help improve outcomes through better procedure planning and execution, and also allow for new innovative approaches, such as the immune stimulatory interstitial laser thermotherapy treatment (imILT®) of CLS, aimed for the interventional oncology market.

About MRI Interventions, Inc.Building on the power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se